Reducing addiction, promoting competition FDA priorities for 2018
The Food and Drug Administration today announced four priority areas for additional policy activity in 2018: reducing addiction to opioid drugs and cigarettes; promoting innovation and competition; empowering consumers to make informed decisions; and strengthening the FDA workforce. Specific policy efforts include new steps to support and streamline development and approval of treatments that address addiction; reducing burdens for creating and approving generic drugs; and extending new hiring and pay authorities to recruit and retain FDA staff.
Related News Articles
Headline
Mary Thompson — a member of AHA’s Committee on Behavioral Health and president of Trillium Place, a mental health and addiction recovery organization…
Blog
More than 16 years ago, the U.S. House of Representatives designated July as National Minority Mental Health Awareness Month. Inspired by the work of author…
Chairperson's File
In this episode, I talk with my colleague Robert Brady, who leads the Anxiety Disorders Service at Dartmouth Health. He specializes in assessing and treating…
Headline
Rosalyn Carpenter, AHA Institute for Diversity and Health Equity Leadership Council member, senior vice president and chief diversity, equity, inclusion and…
Headline
Clinicians bring all of their skill and mental acuity to treat the whole patient, but there are many factors that can derail their ability to provide patient…
Blog
Minority Mental Health Awareness Month is an opportunity to acknowledge that we live in a time when the patients and communities we serve are experiencing the…